<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833948</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI 006 - H-15016807</org_study_id>
    <nct_id>NCT02833948</nct_id>
  </id_info>
  <brief_title>Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)</brief_title>
  <acronym>GALILEO-4D</acronym>
  <official_title>Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardialysis BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aortic valve is located between the left ventricle and the aorta. Patients with
      symptomatic, severe aortic valve stenosis conventionally have it surgically replaced
      requiring direct access to the heart through the chest. Transcatheter aortic valve
      replacement (TAVR) is now a well-established alternative for treating severe aortic valve
      stenosis. Both types of intervention improve prognosis and alleviate symptoms.

      The optimal choice of blood thinning therapy after TAVR is unknown. It has been reported that
      leaflet thrombosis with reduced leaflet motion can occur and this phenomenon has been
      suggested to be potentially related with neurological events. In addition, the occurence of
      this phenomenon can be reduced with anticoagulation blood thinning therapy.

      The purpose of this study is to evaluate if anticoagulation compared to the usual double
      platelet inhibitor therapy after TAVR can reduce the risk of leaflet thrombosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become an established
      therapeutic option for patients with symptomatic, severe aortic valve stenosis, who are
      ineligible or at high risk for conventional surgical aortic valve replacement (SAVR). It was
      recently reported that leaflet thickening and reduced leaflet motion, verified by
      four-dimensional computed tomography (4DCT), was not uncommon after both TAVR and SAVR. It
      has been emphasized that this phenomenon should be further investigated for its effect on
      clinical outcomes (e.g. stroke) and valve durability. As this valve leaflet thickening and
      reduced motion could be reversed by oral anticoagulant (OAC) treatment and was not observed
      in patients on chronic OAC therapy, it has been hypothesized that this phenomenon could be
      related to possible leaflet thrombosis or a &quot;thrombotic film&quot; on the leaflets.

      AIM: To evaluate whether a rivaroxaban-based strategy, following successful TAVR, compared to
      an antiplatelet-based strategy, is superior in reducing subclinical valve leaflet thickening
      and motion abnormalities - as detected by 4DCT-scan.

      POPULATION: All patients undergoing successful TAVR by ileofemoral or subclavian access with
      an approved TAVR device will be screened for eligibility. Included subjects must provide
      written informed consent. Inclusion and exclusion criteria are listed below.

      DESIGN: The GALILEO-4D trial will be conducted as a substudy of the multicenter, open-label,
      randomized, event-driven, active-controlled GALILEO trial. Patients will be 1:1 randomized to
      an antiplatelet-based strategy vs. rivaroxaban-based strategy - the randomization will adopt
      the same 1:1 randomization of the main GALILEO trial. In case the GALILEO-4D trial should
      still be continued after completion of the main GALILEO trial, this 1:1 randomization will be
      continued until inclusion of 150 patients in both treatment groups. In total, 300 patients
      will be randomized in the GALILEO-4D trial.

      INTERVENTION: Subjects in the GALILEO-4D substudy will receive the same intervention as in
      the main GALILEO study. In addition, a 4DCT-scan and echocardiography will be performed at 90
      days after randomization.

      END POINTS: The primary endpoint constitutes the rate of patients with at least one
      prosthetic leaflet with &gt; 50% motion reduction as assessed by cardiac 4DCT-scan (total N =
      300). The secondary endpoints are listed below.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">March 6, 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Patients With at Least One Prosthetic Leaflet With &gt;50% Motion Reduction as Assessed by Cardiac 4DCT-scan</measure>
    <time_frame>3 months</time_frame>
    <description>Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (&lt;50%), (III) moderate to severely reduced (&gt;50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is &gt; 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Rate of Prosthetic Leaflets With &gt; 50% Motion Reduction as Assessed by Cardiac 4DCT-scan</measure>
    <time_frame>3 months</time_frame>
    <description>The rate of prosthetic leaflets with RLM&gt; grade 3 as assessed by cardiac 4DCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan</measure>
    <time_frame>3 months</time_frame>
    <description>The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan</measure>
    <time_frame>3 months</time_frame>
    <description>The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.</measure>
    <time_frame>3 months</time_frame>
    <description>Transprosthetic mean pressure gradiÃ«nt as determined by transthoracic echocardiography at three months after randomization.
scale [0-100]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.</measure>
    <time_frame>3 months</time_frame>
    <description>Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization.
scale [0.1-4.0]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.</measure>
    <time_frame>3 months</time_frame>
    <description>Death, Dichotomization by HALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.</measure>
    <time_frame>3 months</time_frame>
    <description>Death, Dichotomization by RLM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.</measure>
    <time_frame>3 months</time_frame>
    <description>Thromboembolic event, Dichotomization by HALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.</measure>
    <time_frame>3 months</time_frame>
    <description>Thromboembolic event, Dichotomization by RLM</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Ventricular Outflow Obstruction</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>ASA + Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban + ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)</description>
    <arm_group_label>ASA + Clopidogrel</arm_group_label>
    <arm_group_label>Rivaroxaban + ASA</arm_group_label>
    <other_name>Asprin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Drug: Clopidogrel 75 mg OD for first 90 days</description>
    <arm_group_label>ASA + Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)</description>
    <arm_group_label>Rivaroxaban + ASA</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successful TAVR of a native aortic valve stenosis

          -  By iliofemoral or subclavian access

          -  With any approved/marketed TAVR device

          -  Written informed consent

        Exclusion Criteria:

          -  Atrial fibrillation (AF), current or previous, with an ongoing indication for oral
             anticoagulant treatment

          -  Any other indication for continued treatment with any oral anticoagulant

          -  Known bleeding diathesis (such as but not limited to platelet count â¤ 50,000/mm3 at
             screening, hemoglobin level &lt; 8.5 g/dL or &lt; 5.3 mmol/l, history of intracranial
             hemorrhage, or subdural hematoma)

          -  Any indication for dual antiplatelet therapy (DAPT) for more than three months after
             randomization (such as coronary, carotid, or peripheral stent implantation)

          -  Clinically overt stroke within the last three months

          -  Planned coronary or vascular intervention or major surgery

          -  Severe renal insufficiency (eGFR &lt; 30 mL/min/1.73 m2) or on dialysis, or post-TAVR
             unresolved acute kidney injury with renal dysfunction â¥ stage 2

          -  Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic
             disease associated with coagulopathy

          -  Iodine contrast allergy or other condition that prohibits CT imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars SÃ¸ndergaard, MD;DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai M.C</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <zip>AB T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Care</name>
      <address>
        <city>Vancouver</city>
        <zip>ON M1L 1W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus university hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CharitÃ©- UniversitÃ¤tsmedizin Berlin - Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91012</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicin Herzzentrum Lahr/Baden</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig - UniversitÃ¤tsklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum MÃ¼nchen</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Zienkenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus M.C</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkÃ¥ne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, Friedman J, Berman D, Cheng W, Kashif M, Jelnin V, Kliger CA, Guo H, Pichard AD, Weissman NJ, Kapadia S, Manasse E, Bhatt DL, Leon MB, SÃ¸ndergaard L. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med. 2015 Nov 19;373(21):2015-24. doi: 10.1056/NEJMoa1509233. Epub 2015 Oct 5.</citation>
    <PMID>26436963</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <results_first_submitted>December 23, 2019</results_first_submitted>
  <results_first_submitted_qc>January 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Valve Disease</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>TAVR</keyword>
  <keyword>Valve Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Ventricular Outflow Obstruction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02833948/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ASA + Clopidogrel</title>
          <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
        </group>
        <group group_id="P2">
          <title>Rivaroxaban + ASA</title>
          <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>were not scanned</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>scans could not be evaluated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ASA + Clopidogrel</title>
          <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
        </group>
        <group group_id="B2">
          <title>Rivaroxaban + ASA</title>
          <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.5" spread="6.2"/>
                    <measurement group_id="B2" value="79.7" spread="7.3"/>
                    <measurement group_id="B3" value="80.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="5.1"/>
                    <measurement group_id="B2" value="27.7" spread="6.5"/>
                    <measurement group_id="B3" value="27.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS risk score</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" spread="2.1"/>
                    <measurement group_id="B2" value="2.8" spread="1.5"/>
                    <measurement group_id="B3" value="2.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS risk category - High</title>
          <description>The risk model of the Society of Thoracic Surgeons (STS) uses an algorithm that is based on the presence of coexisting illnesses to predict 30-day operative mortality. The STS score equals the predicted mortality expressed as a percentage.
A score of greater than 8% indicates high risk, 3 to 8% intermediate risk, and les than 3% low risk.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS risk category - Intemediate</title>
          <description>The risk model of the Society of Thoracic Surgeons (STS) uses an algorithm that is based on the presence of coexisting illnesses to predict 30-day operative mortality. The STS score equals the predicted mortality expressed as a percentage.
A score of greater than 8% indicates high risk, 3 to 8% intermediate risk, and les than 3% low risk.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS risk category - low</title>
          <description>The risk model of the Society of Thoracic Surgeons (STS) uses an algorithm that is based on the presence of coexisting illnesses to predict 30-day operative mortality. The STS score equals the predicted mortality expressed as a percentage.
A score of greater than 8% indicates high risk, 3 to 8% intermediate risk, and les than 3% low risk.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive Heart Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous stroke</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peripheral Artery disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous venous thromboembolism</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Permanent Pacemaker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic obstructive pulmonary disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular filtration rate</title>
          <units>ml/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.6" spread="19.4"/>
                    <measurement group_id="B2" value="73.6" spread="19.2"/>
                    <measurement group_id="B3" value="75.1" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Valve type - balloon-expandable</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Valve type - Self-expandable</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Valve type - Supra-annular leaflet position</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Valve-in-valve</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post TAVR Echo - Aortic-valve-area</title>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.5"/>
                    <measurement group_id="B2" value="1.8" spread="0.5"/>
                    <measurement group_id="B3" value="1.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post TAVR Echo - mean aortic-valve gradient</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" spread="4"/>
                    <measurement group_id="B2" value="11" spread="5"/>
                    <measurement group_id="B3" value="11" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post TAVR Echo - Left Ventricular ejection fraction</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="10"/>
                    <measurement group_id="B2" value="55" spread="11"/>
                    <measurement group_id="B3" value="56" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paravalvular aortic regurgitation - none or trace</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paravalvular aortic regurgitation - Mild</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paravalvular aortic regurgitation - moderate or severe</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Patients With at Least One Prosthetic Leaflet With &gt;50% Motion Reduction as Assessed by Cardiac 4DCT-scan</title>
        <description>Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (&lt;50%), (III) moderate to severely reduced (&gt;50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is &gt; 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population</population>
        <group_list>
          <group group_id="O1">
            <title>ASA + Clopidogrel</title>
            <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban + ASA</title>
            <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Patients With at Least One Prosthetic Leaflet With &gt;50% Motion Reduction as Assessed by Cardiac 4DCT-scan</title>
          <description>Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (&lt;50%), (III) moderate to severely reduced (&gt;50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is &gt; 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.</description>
          <population>Intention-to-treat (ITT) study population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Fisher Exact</method>
            <method_desc>The Fisherâs exact probability test was used to compare the percentages of patients with the primary end point between the treatment groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Prosthetic Leaflets With &gt; 50% Motion Reduction as Assessed by Cardiac 4DCT-scan</title>
        <description>The rate of prosthetic leaflets with RLM&gt; grade 3 as assessed by cardiac 4DCT</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population</population>
        <group_list>
          <group group_id="O1">
            <title>ASA + Clopidogrel</title>
            <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban + ASA</title>
            <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Prosthetic Leaflets With &gt; 50% Motion Reduction as Assessed by Cardiac 4DCT-scan</title>
          <description>The rate of prosthetic leaflets with RLM&gt; grade 3 as assessed by cardiac 4DCT</description>
          <population>Intention-to-treat (ITT) study population</population>
          <units>leaflets</units>
          <param>Number</param>
          <units_analyzed>leaflets</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>leaflets</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan</title>
        <description>The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT.</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population</population>
        <group_list>
          <group group_id="O1">
            <title>ASA + Clopidogrel</title>
            <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban + ASA</title>
            <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan</title>
          <description>The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT.</description>
          <population>Intention-to-treat (ITT) study population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan</title>
        <description>The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population</population>
        <group_list>
          <group group_id="O1">
            <title>ASA + Clopidogrel</title>
            <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban + ASA</title>
            <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan</title>
          <description>The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan</description>
          <population>Intention-to-treat (ITT) study population</population>
          <units>Leaflets</units>
          <param>Number</param>
          <units_analyzed>Leaflets</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Leaflets</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.</title>
        <description>Transprosthetic mean pressure gradiÃ«nt as determined by transthoracic echocardiography at three months after randomization.
scale [0-100]</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population</population>
        <group_list>
          <group group_id="O1">
            <title>ASA + Clopidogrel</title>
            <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban + ASA</title>
            <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.</title>
          <description>Transprosthetic mean pressure gradiÃ«nt as determined by transthoracic echocardiography at three months after randomization.
scale [0-100]</description>
          <population>Intention-to-treat (ITT) study population</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="5"/>
                    <measurement group_id="O2" value="10" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.</title>
        <description>Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization.
scale [0.1-4.0]</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population</population>
        <group_list>
          <group group_id="O1">
            <title>ASA + Clopidogrel</title>
            <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban + ASA</title>
            <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.</title>
          <description>Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization.
scale [0.1-4.0]</description>
          <population>Intention-to-treat (ITT) study population</population>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.4"/>
                    <measurement group_id="O2" value="1.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.</title>
        <description>Death, Dichotomization by HALT</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population, subgroup of patients with analysable scans</population>
        <group_list>
          <group group_id="O1">
            <title>HALT (-)</title>
            <description>Hypoattenuated leaflet thickening (-)</description>
          </group>
          <group group_id="O2">
            <title>HALT (+)</title>
            <description>Hypoattenuated leaflet thickening (+)</description>
          </group>
        </group_list>
        <measure>
          <title>Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.</title>
          <description>Death, Dichotomization by HALT</description>
          <population>Intention-to-treat (ITT) study population, subgroup of patients with analysable scans</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.</title>
        <description>Death, Dichotomization by RLM</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population, subgroup of patients with analysable scans</population>
        <group_list>
          <group group_id="O1">
            <title>RLM&gt;2 (-)</title>
            <description>Reduced Leaflet Motion &gt;2 (-)</description>
          </group>
          <group group_id="O2">
            <title>RLM(+)</title>
            <description>Reduced Leaflet Motion &gt;2 (+)</description>
          </group>
        </group_list>
        <measure>
          <title>Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.</title>
          <description>Death, Dichotomization by RLM</description>
          <population>Intention-to-treat (ITT) study population, subgroup of patients with analysable scans</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.</title>
        <description>Thromboembolic event, Dichotomization by HALT</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population, subgroup of patients with analysable scans</population>
        <group_list>
          <group group_id="O1">
            <title>HALT (-)</title>
            <description>Hypoattenuated leaflet thickening (-)</description>
          </group>
          <group group_id="O2">
            <title>HALT (+)</title>
            <description>Hypoattenuated leaflet thickening (+)</description>
          </group>
        </group_list>
        <measure>
          <title>Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.</title>
          <description>Thromboembolic event, Dichotomization by HALT</description>
          <population>Intention-to-treat (ITT) study population, subgroup of patients with analysable scans</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.</title>
        <description>Thromboembolic event, Dichotomization by RLM</description>
        <time_frame>3 months</time_frame>
        <population>Intention-to-treat (ITT) study population, subgroup of patients with analysable scans</population>
        <group_list>
          <group group_id="O1">
            <title>RLM&gt;2 (-)</title>
            <description>Reduced Leaflet Motion &gt;2 (-)</description>
          </group>
          <group group_id="O2">
            <title>RLM(+)</title>
            <description>Reduced Leaflet Motion &gt;2 (+)</description>
          </group>
        </group_list>
        <measure>
          <title>Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.</title>
          <description>Thromboembolic event, Dichotomization by RLM</description>
          <population>Intention-to-treat (ITT) study population, subgroup of patients with analysable scans</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <desc>Adverse event reporting was captured via the Main Galileo trial (Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes) NCT02556203</desc>
      <group_list>
        <group group_id="E1">
          <title>ASA + Clopidogrel</title>
          <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Clopidogrel: Drug: Clopidogrel 75 mg OD for first 90 days
If new-onset atrial fibrillation occurred within three months, clopidogrel was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3 and combined with acetylsalicyclic acid 75mg to 100mg once-daily (which was discontinued at three month post-TAVR); however, if new-onset atrial fibrillation occurred after three months, acetylsalicyclic acid 75mg to 100mg once-daily was replaced by vitamin K antagonist targeting an international normalized ratio of 2 to 3.</description>
        </group>
        <group group_id="E2">
          <title>Rivaroxaban + ASA</title>
          <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Acetylsalicylic acid: Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)
Rivaroxaban: Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)
If new-onset atrial fibrillation occurred within this group, the rivaroxaban drug dose was increased from 10mg once-daily to 20mg once-daily (or 15mg once-daily in patients with moderate renal dysfunction as per drug label) plus acetylsalicyclic acid 75mg to 100mg once-daily; acetylsalicyclic acid was discontinued at three months post-TAVR.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Major bleeding event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>minor bleeding</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="116"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ole De Backer, MD, PhD</name_or_title>
      <organization>The Heart Center - Rigshospitalet, Copenhagen, Denmark</organization>
      <phone>+45-35457086</phone>
      <email>ole.debacker@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

